During the presymptomatic stages of T1D, which can last from months to years before clinical presentation, the detection of two or more pancreatic islet autoantibodies (AAbs), such as those against glutamic acid decarboxylase (GADA), insulin (IAA), islet antigen 2 (IA‐2A) and zinc transporter 8 (ZnT8A), is the earliest indication of ongoing beta‐cell autoimmunity and the AAbs constitute the best available biomarker for predicting T1D.2 This evidence concerns the gene INS and type 1 diabetes mellitus.